Therapy News and Research

RSS

Creighton researcher receives NIH grant to study gene, stem cell therapy in coronary artery bypass grafts

A Creighton University researcher has received a National Institutes of Health grant to study the effects of gene and stem cell therapy in coronary artery bypass grafts, a first-of-its-kind undertaking that could transform the procedure, increase survival rates and dramatically reduce the possibility of re-occlusion of the grafted arteries and veins in the procedure.

10 Jun 2015

NYU Langone Medical Center celebrates 65th anniversary of Rusk Rehabilitation

Howard A. Rusk, MD (1901-1989), a tall, soft-spoken physician from NYU Langone Medical Center and widely considered "the father of rehabilitation medicine," set about to establish a facility founded on the belief that care should focus on the whole person—not just on their physical illness or disability, but also on their emotional, psychological, and social needs as well.

10 Jun 2015

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure.

10 Jun 2015

HIV-infected transgender women in US have unmet basic needs, less likely to achieve viral suppression

A new CDC study that combines 3 years of data to produce nationally representative estimates characterizing HIV-infected adults receiving care in the U.S. shows that those who identify as transgender women are significantly less likely to adhere to anti-HIV medication regimens and to achieve viral suppression.

10 Jun 2015

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Researchers at VCU Massey Cancer Center's Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival.

10 Jun 2015

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.

10 Jun 2015

Researchers generate computer models for targeted drug therapy on DIPG cancer cells

The results of a recent study on targeted therapy of a specific type of brain cancer were published by Nature Medicine showing specific progress in cancer treatment.

10 Jun 2015

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

In a small clinical trial, scientists at Johns Hopkins' Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.

9 Jun 2015

Early intervention helps improve intellectual ability, reduces autism symptoms in children

Early intervention for toddlers with autism spectrum disorder helps improve their intellectual ability and reduces autism symptoms years after originally getting treatment, a new study shows.

9 Jun 2015

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of the investigational therapy Praluent (alirocumab) Injection.

9 Jun 2015

Lycera forms exclusive global collaboration with Celgene

Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the formation of an exclusive global collaboration with Celgene Corporation to take forward Lycera's proprietary pipeline for cancer and immune-mediated diseases.

9 Jun 2015

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States.

9 Jun 2015

Duration of antibiotic treatment can be cut by half for complicated abdominal infections

In a finding important for preventing the development of antibiotic-resistant superbugs, researchers at the University of Virginia School of Medicine and 22 other institutions have determined that the duration of antibiotic treatment for complicated abdominal infections can be cut by half and remain equally effective.

9 Jun 2015

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16.

8 Jun 2015

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

Celtaxsys, Inc., a clinical stage drug development company focused on developing novel therapies for inflammatory diseases, today announced the successful completion of a $40M Series D financing led by Domain Partners VIII. Additional investors in the financing include Lumira Capital, RMI Partners, Masters Capital Management and the Georgia Research Alliance Venture Fund.

8 Jun 2015

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

DalCor Pharmaceuticals and the Montreal Heart Institute announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine.

8 Jun 2015

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected.

8 Jun 2015

New study gives insight into the mental health of teens, children with Down syndrome

A new study gives insight into the mental health of children and teens with Down syndrome and the behavioral medications that medical caregivers sometimes prescribe for them.

8 Jun 2015

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Merck Canada Inc. announced today that KEYTRUDATM (pembrolizumab) was authorized for sale with conditions by Health Canada on May 19, 2015. KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body's immune system to fight advanced melanoma, the most serious form of skin cancer. It is the first of a new class of therapies called anti-PD-1s approved in Canada.

8 Jun 2015

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.

7 Jun 2015

Therapy News and Research

Creighton researcher receives NIH grant to study gene, stem cell therapy in coronary artery bypass grafts

NYU Langone Medical Center celebrates 65th anniversary of Rusk Rehabilitation

US cancer physicians explore new approach to help older patients undergoing hematopoietic stem cell transplant

HIV-infected transgender women in US have unmet basic needs, less likely to achieve viral suppression

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Phase 2 study of AR101 meets primary endpoint in patients with peanut allergy

Researchers generate computer models for targeted drug therapy on DIPG cancer cells

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

Early intervention helps improve intellectual ability, reduces autism symptoms in children

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Lycera forms exclusive global collaboration with Celgene

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Duration of antibiotic treatment can be cut by half for complicated abdominal infections

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Celtaxsys closes $40M Series D financing and receives $5M CFFT grant to conduct CTX-4430 Phase 2 trial

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

New therapeutic target discovered for idiopathic pulmonary fibrosis

New study gives insight into the mental health of teens, children with Down syndrome

Merck Canada announces conditional approval of KEYTRUDA (pembrolizumab) for melanoma treatment

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News